U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Lung Non-Small Cell Carcinoma

MedGen UID:
1701032
•Concept ID:
C5206378
•
Neoplastic Process

Definition

Lung non-small cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Professional guidelines

PubMed

EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis.
Liu M, Xiao K, Yang L
Int Immunopharmacol 2023 Jun;119:110001. Epub 2023 Apr 17 doi: 10.1016/j.intimp.2023.110001. PMID: 37075672
Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.
Li DN, Lu WQ, Yang BW, Zhang LY, Jin B, Wang S, Che XF, Li C, Liu YP, Qu XJ
Front Immunol 2021;12:666909. Epub 2021 Jun 2 doi: 10.3389/fimmu.2021.666909. PMID: 34149702Free PMC Article
Immune checkpoint inhibitors for the management of advanced non-small-cell lung carcinoma: a meta-analysis.
Lai LT, Zhan ZY, Feng M, Li F, Lai LF, Zhong LX
Anticancer Drugs 2020 Jul;31(6):637-645. doi: 10.1097/CAD.0000000000000921. PMID: 32058346

Recent clinical studies

Etiology

Non-small cell lung cancer in China.
Chen P, Liu Y, Wen Y, Zhou C
Cancer Commun (Lond) 2022 Oct;42(10):937-970. Epub 2022 Sep 8 doi: 10.1002/cac2.12359. PMID: 36075878Free PMC Article
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
Wu SG, Shih JY
Mol Cancer 2018 Feb 19;17(1):38. doi: 10.1186/s12943-018-0777-1. PMID: 29455650Free PMC Article
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S; ESMO Guidelines Committee
Ann Oncol 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222. PMID: 28881918
Non-small-cell lung cancer.
Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R
Nat Rev Dis Primers 2015 May 21;1:15009. doi: 10.1038/nrdp.2015.9. PMID: 27188576

Diagnosis

Non-small cell lung cancer in China.
Chen P, Liu Y, Wen Y, Zhou C
Cancer Commun (Lond) 2022 Oct;42(10):937-970. Epub 2022 Sep 8 doi: 10.1002/cac2.12359. PMID: 36075878Free PMC Article
Lung cancer.
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS
Lancet 2021 Aug 7;398(10299):535-554. Epub 2021 Jul 21 doi: 10.1016/S0140-6736(21)00312-3. PMID: 34273294
Update 2020: Management of Non-Small Cell Lung Cancer.
Alexander M, Kim SY, Cheng H
Lung 2020 Dec;198(6):897-907. Epub 2020 Nov 11 doi: 10.1007/s00408-020-00407-5. PMID: 33175991Free PMC Article
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S; ESMO Guidelines Committee
Ann Oncol 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222. PMID: 28881918

Therapy

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Yu HA, Yang JC, Hayashi H, Goto Y, Felip E, Reck M, Vigliotti M, Dong Q, Cantero F, Fan PD, Kanai M, Sternberg DW, Jänne PA
Future Oncol 2023 Jun;19(19):1319-1329. Epub 2023 May 22 doi: 10.2217/fon-2022-1250. PMID: 37212796
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends.
Majeed U, Manochakian R, Zhao Y, Lou Y
J Hematol Oncol 2021 Jul 8;14(1):108. doi: 10.1186/s13045-021-01121-2. PMID: 34238332Free PMC Article
Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y
J Hematol Oncol 2020 May 24;13(1):58. doi: 10.1186/s13045-020-00881-7. PMID: 32448366Free PMC Article
The biology and management of non-small cell lung cancer.
Herbst RS, Morgensztern D, Boshoff C
Nature 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. PMID: 29364287
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
Nagasaka M, Gadgeel SM
Expert Rev Anticancer Ther 2018 Jan;18(1):63-70. Epub 2017 Nov 26 doi: 10.1080/14737140.2018.1409624. PMID: 29168933Free PMC Article

Prognosis

The Effect of Advances in Lung-Cancer Treatment on Population Mortality.
Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ
N Engl J Med 2020 Aug 13;383(7):640-649. doi: 10.1056/NEJMoa1916623. PMID: 32786189Free PMC Article
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI
Lancet Oncol 2019 Dec;20(12):1691-1701. Epub 2019 Oct 25 doi: 10.1016/S1470-2045(19)30655-2. PMID: 31669155
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI
Ann Oncol 2019 Jul 1;30(7):1121-1126. doi: 10.1093/annonc/mdz131. PMID: 30980071Free PMC Article
The biology and management of non-small cell lung cancer.
Herbst RS, Morgensztern D, Boshoff C
Nature 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. PMID: 29364287
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S; ESMO Guidelines Committee
Ann Oncol 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222. PMID: 28881918

Clinical prediction guides

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD, Chen K, Dutcher G, Patel I, Pellini B
Int J Mol Sci 2022 Aug 12;23(16) doi: 10.3390/ijms23169006. PMID: 36012272Free PMC Article
Precision medicine in non-small cell lung cancer: Current applications and future directions.
Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M, Büttner R
Semin Cancer Biol 2022 Sep;84:184-198. Epub 2020 Jul 27 doi: 10.1016/j.semcancer.2020.07.009. PMID: 32730814
Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy.
Patel SA, Weiss J
Clin Chest Med 2020 Jun;41(2):237-247. Epub 2020 Apr 16 doi: 10.1016/j.ccm.2020.02.010. PMID: 32402359
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
Wu SG, Shih JY
Mol Cancer 2018 Feb 19;17(1):38. doi: 10.1186/s12943-018-0777-1. PMID: 29455650Free PMC Article

Recent systematic reviews

Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
Wu Y, Verma V, Gay CM, Chen Y, Liang F, Lin Q, Wang J, Zhang W, Hui Z, Zhao M, Wang J, Chang JY
Cancer 2023 Jul 1;129(13):1969-1985. Epub 2023 Mar 30 doi: 10.1002/cncr.34755. PMID: 36994945
Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
Zhang M, Fan Y, Nie L, Wang G, Sun K, Cheng Y
Chest 2022 Jun;161(6):1675-1686. Epub 2022 Jan 11 doi: 10.1016/j.chest.2021.12.656. PMID: 35026298
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y, Liu J, Cai X, Pan Z, Liu J, Yin W, Chen H, Xie Z, Liang H, Wang W, Guo Z, Zhao S, Liang W, He J
BMJ 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460. PMID: 31591158Free PMC Article
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U, Tsourti Z, Vervita K, Peters S
Lung Cancer 2019 Aug;134:127-140. Epub 2019 May 30 doi: 10.1016/j.lungcan.2019.05.029. PMID: 31319971
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
Int J Cancer 2017 Jun 15;140(12):2805-2819. Epub 2017 Mar 27 doi: 10.1002/ijc.30691. PMID: 28295308

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...